Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients

Allan E. Shefrin and Ran D. Goldman
Canadian Family Physician July 2009, 55 (7) 704-706;
Allan E. Shefrin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION Children frequently present to my rural emergency department with asthma exacerbations. Should I prescribe systemic corticosteroids? If so, which systemic corticosteroid should I prescribe?

ANSWER A short course of steroids is indicated in the treatment of asthma exacerbations. Both prednisone (1 to 2 mg/kg daily for 5 days) and dexamethasone (0.3 to 0.6 mg/kg daily for 1 to 5 days) are effective in reducing hospital admissions and unscheduled return to care, with minimal side effects.

Asthma is one of the most common presentations to adult and pediatric emergency departments (EDs), accounting for approximately 10 to 15 of every 1000 visits.1

There are various triggers of acute exacerbation of asthma. Bronchospasm and airway inflammation with edema and mucus production are key physiologic factors leading to clinical symptoms. β-Agonists and other bronchodilators target bronchospasm while corticosteroids reduce the inflammatory response by inhibiting the activation of inflammatory cells and by reducing mediator production, microvascular leakage, and mucus formation.2

Corticosteroids have been used to treat asthma for approximately 50 years. Their benefit in the ED treatment of asthma exacerbations was first demonstrated in 1986.3 In 1990, Tal et al4 showed a similar benefit in children.

Treatment guidelines of the Canadian Thoracic Society, Canadian Association of Emergency Physicians, British Thoracic Society, and American National Asthma Education and Prevention Program recommend the use of systemic corticosteroids for moderate to severe exacerbations of asthma and for mild exacerbations not responsive to bronchodilator therapy.5–7 These published guidelines were developed primarily for use in acute care settings and are helpful in EDs; however, there is very little information available on the use of systemic steroids in ambulatory care settings.

Systemic corticosteroids in asthma exacerbations

The Cochrane Collaboration maintains numerous ongoing systematic reviews of randomized controlled trials of systemic steroids versus placebo in acute exacerbations of asthma in children and adults. In one Cochrane Review, patients who were treated with short courses (ie, 3 to 10 days) of steroids required significantly less care as defined by relapse to additional care within 7 to 10 days (relative risk 0.38, 95% confidence interval [CI] 0.20 to 0.74), fewer hospitalizations (relative risk 0.35, 95% CI 0.13 to 0.95), and less need of β-agonist use (−3.3 activations per day of inhaler; 95% CI −5.6 to −1.0). In addition, patient symptom scores improved with steroid therapy; however, no significant comparisons could be made owing to a lack of standardization in the use and reporting of scores between the studies. The overall incidence of side effects, such as vomiting and headache, was reported as rare, with no significant differences between the groups; this might be partly due to the limited information provided in these studies. No significant differences were identified between different routes of administration. The review concludes that a short course of systemic steroids is beneficial in moderate to severe asthma exacerbations. Mild exacerbations can be treated with β-agonist therapy and inhaled corticosteroids, with the addition of systemic steroids if a patient’s symptoms do not improve.8

In another Cochrane Review, children and adults who were given corticosteroids within 1 hour of presentation were significantly less likely to be admitted to hospital (odds ratio 0.50, 95% CI 0.31 to 0.81; number needed to treat = 8, 95% CI 5 to 21) than those not given steroids. Maximal benefit was observed within 4 to 6 hours of administration of corticosteroids. A benefit in peak expiratory flow rate with a standard mean difference at the end of therapy of 0.54 (95% CI 0.01 to 1.1) was suggested in the treated group.9

Systemic steroids for treating asthma

Oral prednisone and dexamethasone are the currently recommended systemic steroids for moderate to severe asthma exacerbations. Formulations such as hydrocortisone and methylprednisolone can be given parenterally. Studies have found these routes to be equally effective, with the oral route being less painful and invasive.10,11 Prednisone is given for 5 days at a dose of 1 to 2 mg/kg daily (maximum 50 mg/d). Dexamethasone can be given for 1 to 5 days at a dose ranging from 0.3 to 0.6 mg/kg daily. Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours, and is 6 times more potent than prednisone. Prednisone is shorter acting, with a half-life of 18 to 36 hours.12

Recognizing the debate in choice and dose of corticosteroids, the Cochrane Database generated a protocol to investigate this issue in hospitalized patients with asthma, but a review has not yet been published.13

Prednisone vs dexamethasone

Few trials compare oral dexamethasone head-to-head with oral prednisone. In 2001, Qureshi et al14 compared 2 days of dexamethasone (0.6 mg/kg daily; maximum 16 mg/d) to 5 days of prednisone (1 mg/kg daily; maximum 60 mg/d). Dexamethasone had a similar efficacy as measured by relapse rates (7.4% vs 6.9%, P = .84), hospitalization rates (11% vs 12%), and the persistence of symptoms at 10 days (22% vs 21%). The patients treated with dexamethasone had increased compliance (99.6% vs 96%, P = .004) and fewer side effects, such as vomiting (0.3% vs 3%, P = .008). Part of the increased compliance in the dexamethasone group was believed to be owing to patients being discharged from EDs with the medication, whereas prednisone required a prescription to be filled at a pharmacy. Although dispensing medication is feasible in some EDs, it is often not an option in the ambulatory practice setting. Furthermore, dexamethasone is given at a smaller volume and can be mixed with better-tasting syrups to allow for better palatability and therefore compliance.

When dexamethasone (0.6 mg/kg daily) was compared with a higher dose of prednisone (2 mg/kg daily), no statistically significant differences were found in relapse rates (16% vs 8%, P = .27) or in the incidence of vomiting in pediatric patients with asthma exacerbations (10% vs 18%, P = .24).15 However, this study was limited owing to a small sample size and a change in hospital protocol in midstudy.

Because dexamethasone has a long half-life, Altamimi et al16 attempted to determine if a single dose of dexamethasone (0.6 mg/kg) was equal to 5 days of prednisolone (2 mg/kg daily). The single dose of dexamethasone demonstrated no difference in any of the following: hospital admission rates (13.4% dexamethasone vs 14.9% prednisolone), additional β-agonist therapy, return to baseline of patient self-assessment scores (5.21 days vs 5.22 days, respectively, mean difference −0.01; 95% CI −0.70 to 0.68), and mean pulmonary index scores (0.4 vs 0.3, mean difference 0.1; 95% CI −0.25 to 0.45) in children 2 to 16 years of age with mild to moderate asthma.16

In summary, these studies showed that slight differences exist in vomiting and compliance favouring dexamethasone; however, more studies are needed to further investigate these effects. To date, studies support using either prednisone or dexamethasone.

Safety

One of the greatest challenges in using systemic corticosteroids is physicians’, parents’, and patients’ concern regarding potential side effects.17 Short bursts of prednisone at a dose of 1 to 2 mg/kg daily for 5 days showed no effect on bone density, height, and adrenal function at 30 days, but transient decreases were noted in bone deposition and adrenal function.17 Cochrane Reviews fail to identify significant increases in side effects such as nausea, tremor, and headache when compared with placebo, while other potential side effects such as hypertension, hyperglycemia, and behavioural disturbances have not been sufficiently reported.

Conclusion

Short courses of systemic corticosteroids are indicated in the treatment of moderate and severe asthma exacerbations as well as mild exacerbations unresponsive to increased doses of β-agonist therapy and inhaled corticosteroids. Prednisone (1 to 2 mg/kg daily for 5 days) and dexamethasone (0.3 to 0.6 mg/kg daily for 1 to 5 days) are appropriate choices, with some evidence suggesting that dexamethasone might be better tolerated and requires shorter duration of therapy. Side effects of short corticosteroid treatments appear minimal and clinically insignificant. More studies are needed to ascertain the optimal dose, duration, and choice of systemic steroids, especially in the ambulatory care setting.

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program at the BC Children’s Hospital in Vancouver, BC. Dr Shefrin is a member and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    BatesDVBaker-AndersonMSiztoRAsthma attack periodicity: a study of hospital emergency visits in VancouverEnviron Res19905115170
    OpenUrlPubMed
  2. ↵
    TaylorIKShawRJThe mechanism of action of corticosteroids in asthmaRespir Med19938742617
    OpenUrlCrossRefPubMed
  3. ↵
    LittenbergBGluckEHA controlled trial of methylprednisolone in the emergency treatment of acute asthmaN Engl J Med198631431502
    OpenUrlPubMed
  4. ↵
    TalALevyNBearmanJMethylprednisolone therapy for acute asthma in infants and toddlers: a controlled trailPediatrics19908633506
    OpenUrlAbstract/FREE Full Text
  5. ↵
    BeckerABérubéDChadZDolovichMDucharmeFD’UrzoTCanadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004: introduction)CMAJ20051736 SupplS124
    OpenUrlAbstract/FREE Full Text
  6. British Thoracic SocietyBritish guideline on the management of asthmaThorax200863Suppl 41121
    OpenUrlFREE Full Text
  7. ↵
    National Asthma Education and Prevention ProgramExpert panel report 3: guidelines for the diagnosis and management of asthmaBethesda, MDNational Institutes of Health2007Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdfAccessed 2009 Apr 29
  8. ↵
    RoweBHSpoonerCHDucharmeFMBretzlaffJABotaGWCorticosteroids for preventing relapse following acute exacerbations of asthmaCochrane Database Syst Rev20073CD000195
  9. ↵
    RoweBHSpoonerCHDucharmeFMBretzlaffJABotaGWEarly emergency department treatment of acute asthma with systemic corticosteroidsCochrane Database Syst Rev20011CD002178
  10. ↵
    BarnettPLCaputoGLBaskinMKuppermanNIntravenous versus oral corticosteroids in the management of acute asthma in childrenAnn Emerg Med19972922127
    OpenUrlCrossRefPubMed
  11. ↵
    BeckerJMAroraAScarfoneRJSpectorNDFontana-PennMEGracelyEOral versus intravenous corticosteroids in children hospitalized with asthmaJ Allergy Clin Immunol1999103458690
    OpenUrlCrossRefPubMed
  12. ↵
    RepchinskyCCorticosteroids: systemic [product monograph]Compendium of pharmaceuticals and specialtiesOttawa, ONCanadian Pharmacists Association20085746
  13. ↵
    SmithMMcLoughlinLOral and systemic steroids at different doses for acute asthma in hospitalised children [protocol]Cochrane Database Syst Rev20043CD004824
  14. ↵
    QureshiFZaritskyAPoirierMPComparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthmaJ Pediatr20011391206
    OpenUrlCrossRefPubMed
  15. ↵
    GreenbergRAKerbyGRooseveltGEA comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency departmentClin Pediatr (Phila)200847881723Epub 2008 May 8
    OpenUrlAbstract/FREE Full Text
  16. ↵
    AltamimiSRobertsonGJastaniahWDaveyADehghaniNChenRSingle-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthmaPediatr Emerg Care2006221278693
    OpenUrlCrossRefPubMed
  17. ↵
    DucharmeFMChabotGPolychronakosCGlorieuxFMazerBSafety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density and adrenal functionPediatrics2003111237683
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (7)
Canadian Family Physician
Vol. 55, Issue 7
1 Jul 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients
Allan E. Shefrin, Ran D. Goldman
Canadian Family Physician Jul 2009, 55 (7) 704-706;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients
Allan E. Shefrin, Ran D. Goldman
Canadian Family Physician Jul 2009, 55 (7) 704-706;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Systemic corticosteroids in asthma exacerbations
    • Systemic steroids for treating asthma
    • Prednisone vs dexamethasone
    • Safety
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Question 1: Prednisolone or dexamethasone for acute exacerbations of asthma: do they have similar efficacy in the management of exacerbations of childhood asthma?
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Child Health Update

  • Shuddering attacks
  • Continuous positive airway pressure for obstructive sleep apnea in children
  • Henoch-Schönlein purpura in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire